These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35339109)

  • 1. Synergistic effect of antimetabolic and chemotherapy drugs in triple-negative breast cancer.
    López-Camacho E; Trilla-Fuertes L; Gámez-Pozo A; Dapía I; López-Vacas R; Zapater-Moros A; Lumbreras-Herrera MI; Arias P; Zamora P; Vara JÁF; Espinosa E
    Biomed Pharmacother; 2022 May; 149():112844. PubMed ID: 35339109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
    Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
    Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational analysis of image-based drug profiling predicts synergistic drug combinations: applications in triple-negative breast cancer.
    Brandl MB; Pasquier E; Li F; Beck D; Zhang S; Zhao H; Kavallaris M; Wong ST
    Mol Oncol; 2014 Dec; 8(8):1548-60. PubMed ID: 24997502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
    Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
    J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).
    Kwok CW; Treeck O; Buchholz S; Seitz S; Ortmann O; Engel JB
    Target Oncol; 2015 Sep; 10(3):365-73. PubMed ID: 25293576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer.
    Woo SM; Kim AJ; Choi YK; Shin YC; Cho SG; Ko SG
    Phytother Res; 2016 Nov; 30(11):1817-1823. PubMed ID: 27476488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
    Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
    Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLI1-targeting drugs induce replication stress and homologous recombination deficiency and synergize with PARP-targeted therapies in triple negative breast cancer cells.
    Mani C; Tripathi K; Omy TR; Reedy M; Manne U; Palle K
    Biochim Biophys Acta Mol Basis Dis; 2022 Feb; 1868(2):166300. PubMed ID: 34748904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
    Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
    Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the antitumor activity of sphingosine-1-phosphate against human triple-negative breast cancer cells with basal-like morphology.
    Abuhussein O; Yang J
    Invest New Drugs; 2020 Oct; 38(5):1316-1325. PubMed ID: 32060788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer.
    Xue L; Chen F; Yue F; Camacho L; Kothapalli S; Wei G; Huang S; Mo Q; Ma F; Li Y; Jiralerspong S
    Breast Cancer Res Treat; 2021 Jan; 185(1):73-84. PubMed ID: 32940848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
    Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effects of epoxyazadiradione (EAD) and paclitaxel against triple-negative breast cancer cells.
    Sijisha KS; Anusha R; Priya S
    Fundam Clin Pharmacol; 2024 Aug; 38(4):758-766. PubMed ID: 38482560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic Role of Thymoquinone on Anticancer Activity of 5-Fluorouracil in Triple Negative Breast Cancer Cells.
    Zheng M; Mei Z; Junaid M; Tania M; Fu J; Chen HC; Khan MA
    Anticancer Agents Med Chem; 2022; 22(6):1111-1118. PubMed ID: 34170813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    Gohr K; Hamacher A; Engelke LH; Kassack MU
    BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
    Ono H; Sowa Y; Horinaka M; Iizumi Y; Watanabe M; Morita M; Nishimoto E; Taguchi T; Sakai T
    Breast Cancer Res Treat; 2018 Aug; 171(1):43-52. PubMed ID: 29752686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    You KS; Yi YW; Kwak SJ; Seong YS
    Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.